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Summary 
 
1. The effects of bacterial lipopolysaccharide (Escherichia coli 0111-B4; LPS) on coronary 
vascular tone were examined in the isolated perfused rat heart. The role of nitric oxide 
and/or prostaglandin products of the cyclooxygenase pathway in mediating the actions of 
LPS were also investigated. 
 
2. Coronary vascular tone was raised and maintained by a continuous perfusion of the 
thromboxane mimetic U46619 (5 nM). LPS perfusion (0.1 - 100 μg ml-1) caused a 
concentration-dependent fall in coronary tone without any significant change in the force 
of cardiac contractility.  
 
3. At 5 μg ml-1 LPS reduced perfusion pressure by 38 ± 9 mmHg. This effect was rapid  in 
onset, maximal within the first 5 min and sustained for 90 ± 10 min (n=6).  
 
4. The vasodilatation induced by LPS was dependent on the presence of an intact 
endothelium and abolished following endothelial damage caused by air embolism. 
 
5. NG-nitro-L-arginine methylester (L-NAME; 50 μM) or NG-nitro-L-arginine (L-NOARG; 
50 μM) blocked the vasodilatation induced by LPS (5 μg/ml).  The inhibition caused by 
these arginine analogues was partially reversed by 1 mM L- but not D-arginine.   
 
6. The vasodilator action of LPS was also completely blocked by the glucocorticoid 
 dexamethasone (10 μM) but unaffected by indomethacin  (10 μM). 
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7. These results suggest that LPS evokes rapid release of nitric oxide (NO) in the 
microvasculature of the isolated rat heart presumably via activation of the constitutive L-
arginine-NO pathway in the endothelium. Furthermore, the lack of effect of 
indomethacin suggests that prostaglandins released via the cyclooxygenase pathway are 
not involved in mediating this action of LPS. 
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Introduction 
 
 Experimental models of endotoxin shock have shown that administration of bacterial 
lipopolysaccharide (LPS) to animals in vivo results in a characteristic biphasic fall in systemic 
blood pressure in which the first phase of the response occurs rapidly following administration of 
LPS and the second phase develops as a gradual progressive fall in blood pressure after a lag 
phase of about 30 min (Thiemermann & Vane, 1990; Wright et al., 1992). The development of 
the sustained hypotensive response (second phase) is currently attributed mainly to nitric oxide 
(NO) (Kilbourn et al., 1990; Thiemermann & Vane, 1990, Wright et al., 1992), derived from the 
cationic amino acid L-arginine (Palmer et al., 1988a; Schmidt et al., 1988).  Synthesis of NO 
under these conditions involves induction of the Ca2+/calmodulin-independent NO synthase 
previously identified in macrophages (Stuehr & Marletta, 1987; Marletta et al., 1988). 
Expression of this enzyme is time-dependent and involves de novo protein synthesis which can 
be inhibited by the protein synthesis inhibitor cyclohexamide and by the glucocorticoid 
dexamethasone (Knowles et al., 1990; Radomski et al., 1990; Rees et al., 1990a).  Once induced 
the activity of the enzyme can be blocked by inhibitors of NO synthase including NG-
monomethyl-L-arginine (L-NMMA) (Kilbourn et al., 1990; Radomski et al., 1990; Rees et al., 
1990a; Thiemermann & Vane, 1990, Wright et al., 1992). 
 
 In addition to the inducible enzyme there is also a constitutive Ca2+/calmodulin 
dependent NO synthase which generates NO in the endothelium under normal physiological 
conditions. NO released via this pathway regulates blood flow and is thought to maintain the 
cardiovascular system in a constant state of vasodilatation (Rees et al., 1990b; see Moncada et 
al., 1991 for review).  At present it is not clear whether, in the vasculature, this enzyme is also 
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activated by LPS and whether NO released via the constitutive pathway plays any role in 
maintaining the deleterious actions of LPS either in vivo or in vitro.  In this context it is of 
interest that in rats both the initial and sustained phases of the vasodilator response to LPS are 
attenuated by L-NMMA (Thiemermann & Vane, 1990), suggesting that NO may be released 
acutely by LPS in the earlier stages of endotoxic shock.  This hypothesis however remains to be 
substantiated, since in similar studies L-NMMA did not inhibit the initial action of LPS in 
lowering arterial blood pressure in rabbits (Wright et al., 1992). 
 
 In the present study we have investigated the effects of LPS in the isolated perfused rat 
heart with the aim of establishing whether coronary tone can be altered acutely by a direct action 
of LPS on the microvasculature. Using inhibitors of nitric oxide synthase, NG-nitro-L-arginine 
(Moore et al., 1990; Ishii et al., 1990) and NG-nitro-L-arginine methylester (Rees et al., 1990b), 
we have also examined whether NO is released acutely in response to LPS and whether this may 
mediate the effects of LPS in the microvasculature of the rat heart.  Furthermore, since LPS is 
known to activate phospholipase A2 (Liu & Takeda, 1982) and thereby elevate prostaglandin 
synthesis we have assessed whether inhibition of the cyclooxygenase pathway influenced the 
actions of LPS in the rat heart. 
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Methods 
Isolation and perfusion of the rat heart 
 Hearts obtained from male Sprague-Dawley rats (200-350 g) were perfused by a 
modified Langendorff technique as described previously (Baydoun & Woodward, 1991).  
Briefly, hearts were perfused at a constant rate of 10 ml min-1 with Krebs-Henseleit buffer 
maintained at 37oC and equilibrated with 95 % oxygen and 5 % carbon dioxide. Coronary 
perfusion pressure was monitored continuously using a pressure transducer attached to an aortic 
cannula. The force of cardiac contraction was measured with a tension transducer attached to the 
apex of the heart. Each heart was allowed to equilibrate for a minimum period of 20 min prior to 
beginning an experimental protocol.  
 
 In some experiments, coronary tone was raised and maintained using the thromboxane-
mimetic, 9,11-dideoxy-11α,9α-epoxymethano-prostaglandin F2α (U46619; 5 nM). When 
applied, E. coli lipopolysaccharide (LPS) was dissolved in Krebs buffer and perfused 
continuously through the heart.  Maximal doses of bradykinin (BK, 1 nmol) and sodium 
nitroprusside (SNP; 10 nmoles), used in a previous study (Baydoun & Woodward, 1991), were 
applied as bolus injections into the perfusate, 3 cm proximal to the aortic cannula. All other 
agents, including indomethacin (10 μM), dexamethasone (10 μM), NG-nitro-L-arginine (L-
NOArg; 50 μM) and NG-nitro-L-arginine methylester (L-NAME; 50 μM) were added to the 
buffer reservoir and perfused through the heart for a minimum period of 30 min before obtaining 
responses to LPS (5 μg ml-1). In other experiments dexamethasone (10 μM) or L-NAME (50 
μM) was administered after the vasodilator response to LPS (5 μg ml-1) had reached a maximum. 
The dependency of the vasodilator action of LPS on an intact endothelium was investigated after 
damaging the endothelium by injecting 1 ml bolus of air into the coronary circulation as 
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previously described (Baydoun et al., 1989). 
 
Materials 
 Bradykinin, sodium nitroprusside, Escherichia coli lipopolysaccharide (serotype: 0111 
B4), indomethacin, dexamethasone, 9,11-dideoxy-11α,9α-epoxymethano-prostaglandin F2α, L-
NG-nitro arginine, L-NG-nitro arginine methylester, L- and D-arginine were obtained from Sigma 
(Pool, Dorset).  All other reagents were of analytical grade and purchased from British Drug 
House (Poole, Dorset). 
 
Statistical analysis 
 Results are representative of observations in at least three separate hearts and are 
expressed as mean ± S.E. of n experiments. Statistical significance was assessed using a 
Student's t-test and values of P < 0.05 were considered significant.   
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Results 
Vasodilator action of bacterial lipopolysaccharide  
 Coronary tone was raised in each experiment prior to the administration of LPS by 
continuous perfusion of the thromboxane mimetic U46619. At 5 nM U46619 increased perfusion 
pressure from a basal value of 44 ± 6 mmHg to 120 ± 15 mmHg (n = 9). Cumulative application 
of LPS (0.1 - 100 μg ml-1) caused a rapid, concentration-dependent decrease in coronary tone 
(Fig 1). At 5 μg ml-1, the lowest concentration required to initiate a reproducible sustained 
response, LPS induced a maximum fall in perfusion pressure of 38 ± 9 mmHg (n = 6).  This 
response was maximal within 5 min and reversible upon the removal of LPS from the perfusate. 
Subsequent administration of LPS to the same tissue, after a 50 min washout period, resulted in a 
marked reduction in the response compared with that previously observed (Fig. 2).  
 
  During continuous infusion of LPS (5 μg ml-1; Fig. 3), the vasodilatation induced was 
sustained for 30 ± 2 min before recovering, requiring a further 60 ± 10 min to return to the pre-
LPS level (n=3). Cardiac contractility was not altered over this time period (Fig. 3). Furthermore, 
continued infusion of LPS after this period did not result in any additional decrease in perfusion 
pressure nor did it cause a loss in the responsiveness to the vasoconstrictor U46619 (5 nM). 
Following recovery, coronary tone was maintained at 120 ± 14.4 mmHg (n=3) for a further 3 h 
in the continued presence of both LPS and U46619.  
 
Effects of NO synthase inhibitors on LPS-induced vasodilatation 
 NG-Nitro-L-arginine methylester (L-NAME; 50 μM) or NG-nitro-L-arginine (L-NOArg; 
50 μM) produced a maintained rise in perfusion pressure, increasing basal coronary tone by 81 ± 
19 mmHg (n = 6) and 75 ± 5 mmHg (n = 3) respectively. The vasoconstriction caused by either 
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compound was partially reversed by L- but not  
D-arginine (1mM), and appeared to be endothelium-dependent as it was abolished by the 
passage of air through the heart. Perfusion of L-arginine (1 mM) had no significant effect on 
coronary tone in the absence of either L-NAME or L-NOARG but respectively reduced the 
vasoconstriction caused by these compounds by 18 ± 3 mmHg (n = 5) and 15 ± 2 mmHg (n = 3). 
  
 
 Infusion of L-NAME (50 μM) through hearts 30 min prior to the application of LPS (5 
μg ml-1) completely blocked the vasodilatation induced by LPS (Fig 4) in four, and reduced the 
response by 50 and 75 % respectively in two out of six hearts. In the experiments where 
complete inhibition was not achieved, the vasodilator response to LPS was only short-lived in 
that the fall in pressure returned to control levels within 8 min. In addition, L-NAME (50 μM) 
reversed the vasodilatation caused by LPS when added to the perfusate after the response to LPS 
had reached a maximum. Similar results were also obtained using L-NOArg (50 μM) which 
completely blocked the vasodilator action of LPS in 3 seperate experiments.  The inhibition 
caused by either of these arginine analogues was partially reversed by L- arginine (1 mM).  
 
  The above findings suggest that nitric oxide may be released acutely in the 
microvasculature of the rat heart in response to LPS. We therefore investigated whether the 
gradual recovery of the vasodilator action of LPS (Fig 3) was due to the depletion of L-arginine, 
the substrate for nitric oxide biosynthesis. In these experiments, addition of L-arginine (1 mM) to 
the buffer reservoir after the vasodilatation to LPS had returned to its pre-LPS level failed to 
elicit a drop in coronary perfusion pressure. Furthermore, inclusion of L-arginine (1mM) in the 
perfusate at the start of LPS infusion failed to prolong the vasodilator action of LPS (data not 
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shown).  
 
Endothelium-dependent vasodilator action of LPS 
 Continuous perfusion of the isolated rat heart with bradykinin (BK) results in a rapid 
desensitization, and thus it could only be applied in bolus doses (unpublished observations).  
Administration of either BK (1 nmol) or sodium nitroprusside (SNP; 10 nmol) to the intact 
perfused rat heart, with tone raised by U46619 (5 nM), produced a marked fall in coronary tone, 
respectively reducing perfusion pressure by 68 ± 5 mmHg (n = 5) and 66 ± 3 mmHg (n = 5).  
The responses to these agents were characteristically different from that obtained with LPS in 
that they were rapid in onset, reaching a maximum within 30 s.  
 
  Application of air (1 ml) to the intact heart had no significant effect on the maximal 
vasodilator action of SNP but completely abolished the vasodilatation produced by BK and LPS. 
When administered to hearts after air embolism, BK (1 nmol) initiated a marked vasoconstriction 
response, increasing perfusion pressure by 45 ± 3 mmHg (Fig. 5; n = 4). 
 
Effects of indomethacin on LPS-induced vasodilatation   
 Perfusion of isolated rat hearts with indomethacin (10 μM) caused a marked drop in 
coronary tone (Fig 6), reducing perfusion pressure from 102 ± 12 mmHg to 58 ± 4 mmHg (n = 
3). To maintain the coronary tone at its previous elevated level the concentration of U46619 was 
raised to 10 nM.  
 
 In three separate experiments indomethacin (10 μM) did not significantly modify the 
vasodilator actions of LPS.  Under these conditions both the magnitude  (43 ± 9 mmHg; n =3) 
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and duration (94 ± 15 min; n = 3) of the LPS vasodilator response was maintained even though 
hearts had been perfused with indomethacin for 30 min prior to and during the LPS challenge 
(Fig 6). 
 
 
Effects of dexamethasone on LPS-induced vasodilatation   
 In contrast to indomethacin, infusion of dexamethasone (10 μM) 30 min prior to LPS 
administration completely blocked the vasodilator action of LPS. Interestingly, when added to 
the perfusate after the response to LPS had reached a maximum, dexamethasone failed to reverse 
the vasodilatation induced by LPS (data not shown). 
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Discussion 
 The data obtained in this study show that LPS is a potent vasodilator agent in the 
microvasculature of the isolated rat heart, causing an acute drop in coronary tone which was 
rapid in onset and sustained over a prolonged period. Following recovery, perfusion pressure was 
maintained at its pre-LPS levels for periods of up to 3 hours without any loss of vascular tone 
even though hearts were continually perfused with LPS and U46619. This lack of hyporeactivity 
to U46619, following prolonged exposure to LPS, is in contrast to findings in isolated rat aortic 
rings in which exposure to LPS for 4 h results in a hyporeactive response to phenylephrine (Rees 
et al., 1990a) and norepinephrine (Julou-Schaeffer et al., 1991; Fleming et al., 1990). This effect 
has been attributed to induction of NO biosynthesis, as it could be potentiated by L-arginine and 
abolished by L-NMMA (Rees et al., 1990a; Julou-Schaeffer et al., 1991; Fleming et al., 1990).  
 
 Lack of a sustained loss in coronary tone under our experimental conditions indicates 
that induction of the Ca2+/calmodulin-independent NO synthase may not occur in the 
microvasculature of the rat heart in vitro. It is likely however that under in vivo conditions LPS 
could induce NO synthase in the coronary vessels of the rat. Indeed in other studies, 
vasoconstrictor responses of isolated perfused rabbit hearts to U46619 were significantly reduced 
if the animals were preexposed to LPS for 4 h prior to isolation of the hearts (Smith et al., 1991). 
The fact that large blood vessels (aorta) can be induced in vitro whereas resistance vessels could 
not perhaps reflects a difference between macrovascular and microvascular tissues.  
Alternatively, it is possible that in the rat heart marked desensitization to LPS occurs following 
the initial vasodilator response. This would explain the recovery of vascular tone after ~ 90 min 
and the inability of continued LPS administration to sustain the vasodilatation.  Furthermore, 
since L-arginine did not maintain the LPS-mediated response, this suggests that depletion of 
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cellular L-arginine did limit production of NO.  
 
 The inhibition of LPS-induced vasodilatation caused by L-NAME and L-NOArg, both 
competitive inhibitors of NO synthase (Ishii et al., 1990; Moore et al., 1990; Rees et al., 1990b), 
strongly suggests that NO is a mediator of this effect. More importantly, it indicates that LPS can 
cause NO release acutely in the microvasculature of the isolated rat heart. The rapidity in onset 
of the response suggests that under these conditions synthesis and release of NO does not involve 
induction of the Ca2+/calmodulin-insensitive NO synthase but instead the activation of the 
constitutive pathway in endothelium. This finding is further substantiated by recent studies 
showing that exposure of cultured endothelial cells to LPS results in the rapid release (within 1 
min) of a NO-like factor which was capable of inhibiting platelet aggregation (Salvemini et al., 
1990). In addition, it also lends support to the hypothesis that acute release of NO in vivo may in 
part mediate the early hypotensive response observed following administration of LPS to rats 
(Thiemermann & Vane, 1990). 
 
 In our studies both L-NAME and L-NOArg caused a marked increase in perfusion 
pressure, in the absence of U46619, indicating that NO is released basally in the rat coronary 
microcirculation.  This finding is consistent with studies in other tissues in vitro (Amezcua et al., 
1989; Moore et al., 1990; Palmer et al., 1988b; Rees et al., 1989a; 1990b) and in vivo (Aisaka et 
al., 1989; Gardiner et al., 1990; Rees et al., 1989b, 1990b) and further strengthens the belief that 
basal release of NO modulates vascular tone (Amrani et al., 1992; Rees et al., 1990b; see 
Moncada et al., 1991). 
 
 In the vasculature, constitutive NO synthase is localized entirely in the endothelial layer 
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(Knowles et al., 1990).  Our observation that the vasodilator action of LPS was endothelium-
dependent and abolished following perfusion of air through the coronary circulation further 
supports the concept that LPS activates constitutive NO synthase in endothelium. Under these 
conditions the vasodilator action of bradykinin, an endothelium-dependent vasodilator, was 
abolished whereas responses to the endothelium-independent vasodilator sodium nitroprusside 
were maintained. Thus, following air embolism endothelial function is impaired with the smooth 
muscle layer remaining virtually intact. The underlying mechanism for the vasoconstrictor action 
of bradykinin following endothelial damage is as yet unclear but may involve a direct action of 
this peptide on the vascular smooth muscle. 
 
 The data from the present study implicates the constitutive, rather than the inducible, L-
arginine-NO pathway in the actions of LPS in the isolated rat heart. It is therefore paradoxical 
that the vasodilatation caused by LPS within 5 min of administration could be inhibited by 
pretreatment with the glucocorticoid dexamethasone. In other studies dexamethasone blocks 
induction of the Ca2+/calmodulin-independent NO synthase but does not affect the activity of 
either the constitutive or the induced enzyme (Radomski et al., 1990; Rees et al., 1990a). The 
mechanism by which dexamethasone exerts its inhibitory action in our study is yet to be 
established.  
 
 Dexamethasone has a wide spectrum of activity and, in addition to preventing the 
expression of inducible NO synthase, can also block metabolism of membrane phospholipid to 
arachidonic acid and thus inhibit production of vasoactive prostanoids including prostacyclin. If 
prostacyclin were involved in mediating the effects of LPS, then inhibition of its synthesis would 
account for the actions of dexamethasone.  However, our data obtained with indomethacin 
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suggest that cyclooxygenase products are not released in the rat heart following administration of 
LPS. Indeed it is questionable whether vasodilator products from this pathway are involved in 
regulating vascular tone in the rat heart in vitro.  In previous studies we could not detect 
significant changes in prostacyclin levels in the effluent collected from rat hearts stimulated with 
bradykinin (Baydoun & Woodward, 1991). The fact that perfusion with indomethacin (Fig. 6), or 
flurbiprofen (Baydoun et al., 1990), results in a marked fall in coronary perfusion pressure 
suggests that vasoconstrictor prostaglandins are released basally in the rat heart and contribute to 
the maintenance of vascular tone. 
 
 One possible mechanism by which dexamethasone can exert its inhibitory action would 
be by preventing the binding of LPS to its recognition sites on the endothelium.  This hypothesis 
is supported by recent studies in mouse peritoneal macrophages in which binding of tritium-
labelled LPS was strongly blocked by dexamethasone, over the same concentration range as used 
in our study (Tahri-Jouti & Chaby., 1990).  The fact that dexamethasone could not reverse a 
vasodilatation induced by LPS suggests that LPS may avidly bind to its recognition sites on the 
endothelium and may not be easily displaced. 
 
 In summary, the data obtained from the present study show that LPS is a potent 
vasodilator agent in the microvasculature of the isolated rat heart.  This action of LPS is 
endothelium-dependent, rapid in onset and maintained over 90 min. Furthermore, it is unaffected 
by indomethacin but susceptible to inhibition by NO synthase inhibitors. This inhibition by the 
L-arginine analogues is partially reversed by L-arginine, suggesting that the vasodilator action of 
LPS in the fine resistance vessels of the rat heart may be mediated by NO synthesized by the 
Ca2+/calmodulin dependent NO synthase. More importantly, it delineates a crucial pathogenic 
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role for NO, synthesized via the constitutive pathway, in the initial hypotension observed in the 
earlier stages of endotoxic shock. 
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Figure 1. Concentration response curve to bacterial lipopolysaccharide (LPS) in the 
isolated perfused rat heart. The graph shows the mean with s.e. of the mean 
indicated by the vertical bars (n = 3). 
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Figure 2. Representative tracing of the vasodilatation induced in the isolated rat heart by 
  acute perfusion of bacterial lipopolysaccharide (LPS). PP denotes coronary  
 perfusion pressure. 
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Figure 3. Representative tracing of the vasodilatation induced in the isolated rat heart  
 by prolonged perfusion of bacterial lipopolysaccharide (LPS). PP denotes   
 coronary perfusion pressure and DT the developed tension. 
 
  
 
 25
 
Figure 4. Inhibition of the vasodilator action of bacterial lipopolysaccharide (LPS)  
  by NG-nitro-L-arginine methylester (L-NAME) and the partial reversal of the 
  inhibition by L-arginine (L-Arg). 
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Figure 5. Effect of perfusion of air (1 ml) through the coronary circulation of the isolated 
rat heart on the vasodilator responses to bolus injections of bradykinin (BK) and 
sodium nitroprusside (SNP) and to continuous perfusion of bacterial 
lipopolysaccharide (LPS).    
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Figure 6. Effects of indomethacin (Ind) on coronary perfusion pressure (PP) and LPS-
induced vasodilatation in the isolated perfused rat heart. 
 
